Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jansen

Showing results (971-980 of 1,087) with videos related to

Pageof 109
Sort By:
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Successful Transfer of Umbilical Cord Blood CD34<sup>+</sup> Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia PatientsHarry Dolstra, Mieke W H Roeven, Jan Spanholtz, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Stroke and Vascular Neurology|April 8, 2021
Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well: results from the MR CLEAN RegistryLuuk Dekker, Esmee Venema, F Anne V Pirson, et al.
Blood Neoplasia|June 22, 2026
Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interferenceMarta Lustig, Maja Kowol, Alina M Hartmann, et al.
Oncotarget|June 8, 2018
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemiaAbhishek A Singh, Francesca Petraglia, Angela Nebbioso, et al.
Neuro-Oncology|June 7, 2014
Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteriaMarc H Jansen, Sophie E Veldhuijzen van Zanten, Esther Sanchez Aliaga, et al.
Frontiers in Immunology|March 8, 2024
The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia AIlja Oomen, Marieke Verhagen, Mariarosaria Miranda, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Leukemia|September 6, 2017
C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiationA E Marneth, K H M Prange, A S A Al Hinai, et al.
Pageof 109

Showing results (971-980 of 1,087) with videos related to

Sort By:
Pageof 109
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Successful Transfer of Umbilical Cord Blood CD34<sup>+</sup> Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia PatientsHarry Dolstra, Mieke W H Roeven, Jan Spanholtz, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Stroke and Vascular Neurology|April 8, 2021
Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well: results from the MR CLEAN RegistryLuuk Dekker, Esmee Venema, F Anne V Pirson, et al.
Blood Neoplasia|June 22, 2026
Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interferenceMarta Lustig, Maja Kowol, Alina M Hartmann, et al.
Oncotarget|June 8, 2018
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemiaAbhishek A Singh, Francesca Petraglia, Angela Nebbioso, et al.
Neuro-Oncology|June 7, 2014
Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteriaMarc H Jansen, Sophie E Veldhuijzen van Zanten, Esther Sanchez Aliaga, et al.
Frontiers in Immunology|March 8, 2024
The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia AIlja Oomen, Marieke Verhagen, Mariarosaria Miranda, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Leukemia|September 6, 2017
C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiationA E Marneth, K H M Prange, A S A Al Hinai, et al.
Pageof 109